BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma

Completed · Phase 1/Phase 2

Conditions studied: Sarcoma

In brief

Phase I/II trial to study the effectiveness of BMS-275291 in treating patients who have HIV-related Kaposi's sarcoma. Drugs such as BMS-275291 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.

Key facts

Study ID

NCT00024024

Run by

National Cancer Institute (NCI)

People needed

59

Starts

2001-08-01

Last updated by the study team

2013-02-11

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Robert H. Lurie Comprehensive Cancer Center, Northwestern University — Chicago, Illinois, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• Herbert Irving Comprehensive Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.